国药控股

最新新闻

• 评级变动
  Sinopharm Group Co., Ltd. (600511): Parent Company Maintains Growth; Plans to Sell Guorui Pharmaceutical to Optimize Asset Structure
  CICC · 2026/8/21
• 公司公告
  JiQiang Bio: Risk Disposal Plan for Conducting Deposit, Loan, and Other Financial Services at Sinopharm Group Finance Co., Ltd.
  SZSI · 2026/9/2
• 评级变动
  Sinopharm Holdings (01099.HK): Results in line with expectations; the retail segment continues to grow rapidly.
  CICC · 2026/8/25
• 公司公告
  Sinopharm Shares: Legal Opinion of Beijing Guofeng Law Firm Regarding the Third Extraordinary Shareholders' Meeting of Sinopharm Group Pharmaceutical Co., Ltd. for 2026
  SZSI · 2026/9/5
• Sinopharm Group (01099) elects Jin Bin as Chairman of the Board.
  Zhitong Finance · 2026/9/15
• 评级变动
  Sinopharm Group Co., Ltd. (000028): Amid Pressure on Distribution and Retail, the Retail Business Continues to Improve
  Huatai Securities · 2026/8/29
• 公司公告
  Sinopharm Group Co., Ltd.: 000028 Sinopharm Group Investor Relations Management Information, September 18, 2026
  SZSI · 2026/9/18
• 评级变动
  CSC Financial: Reiterates 'Buy' rating for Sinopharm Group (01099); Q3 performance in line with prior expectations.
  Zhitong Finance · 2025/11/11
• 评级变动
  Sinopharm Group Co., Ltd. (600511): Parent Company Demonstrates Steady Growth; H2 Growth Expected to Accelerate
  China Securities Co., Ltd. · 2026/8/28
• 评级变动
  Cinda Securities: Initiated coverage on Sinopharm Group (01099.HK) with a 'Buy' rating; profit margins have shown significant improvement.
  Zhitong Finance · 2025/12/9
• 评级变动
  Sinopharm United (000028): Advancing Quality and Efficiency Improvements & Structural Optimization; the operating performance of Guoda Pharmacy Continues to Improve.
  Huayuan Securities · 2026/5/17
• 评级变动
  Nomura Adjusts Sinopharm Group's Price Target to HK$24.23 From HK$23.40, Keeps at Buy
  MT Newswires · 2026/3/24
• 评级变动
  Sinopharm Group Co., Ltd. (000028): Earnings forecast in line with expectations; the year-on-year declines in revenue and profit continue to narrow.
  CICC · 2026/8/18
• Sinopharm Group (01099.HK) saw its H-share holdings increased by Lazard Asset Management LLC by 959,600 shares, valued at approximately HK$15.04 million.
  \u5e02\u573a\u8d44\u8baf · 2026/9/10
• 公司公告
  Jiqiang Bio: Report on the Ongoing Risk Assessment of Sinopharm Group Finance Co., Ltd.
  SZSI · 2026/9/2
• 公司公告
  JiQiang Bio: Announcement Regarding the Proposed Renewal of the Financial Services Agreement with Sinopharm Group Finance Co., Ltd. and Related Party Transactions
  SZSI · 2026/9/2
• 评级变动
  Sinopharm Group Co., Ltd. (600511): Revenue Remains Stable, but Profit Dragged by Certain Subsidiaries
  Huatai Securities · 2026/8/20
• Jiuqiang Biology (300406.SZ): Plans to Renew the Financial Services Agreement with Sinopharm Group Finance Co., Ltd.
  Gelonghui Finance · 2026/9/1
• FMR LLC reduced its stake in Sinopharm Group Co., Ltd. (01099) by 732,400 shares at approximately HK$15.01 per share.
  Zhitong Finance · 2026/9/27
• Sinopharm Modern: Net profit for the first three quarters is expected to decline by 59.30% to 63.05% year-on-year.
  Latest · 2026/10/14
• Lazard Asset Management LLC reduced its stake in Sinopharm Group Holding (01099) by 738,800 shares at approximately HK$15.1 per share.
  Zhitong Finance · 2026/9/27
• Sinopharm Modern (600420.SH): Exports of penicillin-type pharmaceutical intermediates and active pharmaceutical ingredients are primarily directed to Asian countries such as India, South Korea, and Thailand.
  Gelonghui Finance · 2026/9/24
• Sinopharm Group (01099) proposes the re-election of Lian Wanyong as an executive director of the seventh board of directors.
  Zhitong Finance · 2026/8/24

新闻标题为自动聚合内容，未经我们团队独立核实或编辑。